JP2022510346A - 抗菌アンチセンス剤 - Google Patents

抗菌アンチセンス剤 Download PDF

Info

Publication number
JP2022510346A
JP2022510346A JP2021531369A JP2021531369A JP2022510346A JP 2022510346 A JP2022510346 A JP 2022510346A JP 2021531369 A JP2021531369 A JP 2021531369A JP 2021531369 A JP2021531369 A JP 2021531369A JP 2022510346 A JP2022510346 A JP 2022510346A
Authority
JP
Japan
Prior art keywords
compound according
alkyl
acid
group
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510346A5 (https=
Inventor
マーティン・キベル
ティモシー・シュルツ－ウーテルモール
フレイザー・マリー
Original Assignee
ペダニウス・セラピューティクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペダニウス・セラピューティクス・リミテッド filed Critical ペダニウス・セラピューティクス・リミテッド
Publication of JP2022510346A publication Critical patent/JP2022510346A/ja
Publication of JP2022510346A5 publication Critical patent/JP2022510346A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021531369A 2018-11-28 2019-11-27 抗菌アンチセンス剤 Pending JP2022510346A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1819399.5 2018-11-28
GB1819399.5A GB2579253A (en) 2018-11-28 2018-11-28 Antibacterial antisense agents
PCT/GB2019/053354 WO2020109792A1 (en) 2018-11-28 2019-11-27 Antibacterial antisense agents

Publications (2)

Publication Number Publication Date
JP2022510346A true JP2022510346A (ja) 2022-01-26
JP2022510346A5 JP2022510346A5 (https=) 2022-11-09

Family

ID=65024582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531369A Pending JP2022510346A (ja) 2018-11-28 2019-11-27 抗菌アンチセンス剤

Country Status (9)

Country Link
US (1) US20220106595A1 (https=)
EP (1) EP3887520A1 (https=)
JP (1) JP2022510346A (https=)
KR (1) KR20210098493A (https=)
CN (1) CN113366107A (https=)
AU (1) AU2019386368A1 (https=)
CA (1) CA3121064A1 (https=)
GB (1) GB2579253A (https=)
WO (1) WO2020109792A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104530A1 (en) * 2005-03-28 2006-10-05 Cell Works Therapeutics, Inc. Therapeutics targeted to renal cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130516A (en) * 1978-03-31 1979-10-09 Yuuichi Yamamura Acyllnnacetylmuramylpeptide derivativeeantigen combination
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
EP0541486A1 (de) 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclische Konjugate
US20140073589A1 (en) 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
EP3564374A1 (en) * 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
WO2015006740A2 (en) * 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
EP2845607A1 (en) 2013-09-09 2015-03-11 University of Vienna Antisense oligonucleotides with improved pharmacokinetic properties
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
CA2948568A1 (en) 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
EP3240794A4 (en) 2014-12-31 2018-10-31 Oregon State University Antisense antibacterial compounds and methods
WO2016172615A1 (en) 2015-04-24 2016-10-27 University Of Delaware Synthetic n-acetyl-muramic acid derivatives and uses thereof
WO2017010575A1 (ja) * 2015-07-16 2017-01-19 協和発酵キリン株式会社 β２ＧＰＩ遺伝子発現抑制核酸複合体
US11142764B2 (en) 2015-12-23 2021-10-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2016379399B2 (en) 2015-12-23 2022-12-08 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US11180756B2 (en) * 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104530A1 (en) * 2005-03-28 2006-10-05 Cell Works Therapeutics, Inc. Therapeutics targeted to renal cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS CHEM. BIOL., vol. 11, JPN6023040682, 2016, pages 2626 - 2635, ISSN: 0005170294 *

Also Published As

Publication number Publication date
CA3121064A1 (en) 2020-06-04
AU2019386368A1 (en) 2021-07-01
KR20210098493A (ko) 2021-08-10
WO2020109792A1 (en) 2020-06-04
CN113366107A (zh) 2021-09-07
GB2579253A (en) 2020-06-17
GB201819399D0 (en) 2019-01-09
EP3887520A1 (en) 2021-10-06
US20220106595A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
EP2791139B1 (en) Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
US20240026360A1 (en) Oligonucleotides for modulating tau expression
KR101707437B1 (ko) 구아니딘 가교를 갖는 인공 뉴클레오시드 및 올리고뉴클레오티드
CN102596983A (zh) 交联型人工核苷和核苷酸
KR20160068775A (ko) 선택적으로 치환된 퀴놀린 화합물
WO2018002105A1 (en) Antisense oligonucleotides for modulating htra1 expression
EP4692103A1 (en) Novel targeting compound and use thereof, and nucleic acid conjugate and use thereof
JP2022510346A (ja) 抗菌アンチセンス剤
WO2019115416A2 (en) Oligonucleotides for modulating fndc3b expression
EP2440533B1 (en) Guanine riboswitch binding compounds and their use as antibiotics
US20240294915A1 (en) Oligonucleotides for Modulating Apolipoprotein E4 Expression
WO2019137974A1 (en) Oligonucleotides for modulating gsk3b expression
CN111808105A (zh) 含有并环基团的嘧啶酮并吡唑类化合物、其制备方法及用途
WO2025252669A1 (en) Modified oligonucleotides for reducing atxn3 expression
WO2023118359A1 (en) Rhabdobranins and their medical use
BR122024023306A2 (pt) Oligonucleotídeos para modulação da expressão tau
WO2019145386A1 (en) Oligonucleotides for modulating csnk1d expression
KR101116754B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 6-아미노-ν-하이드록시헥산아마이드 화합물 및 이의 제조방법
WO2019141656A1 (en) Oligonucleotides for modulating erc1 expression
HK40005788A (en) Oligonucleotide compositions and methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240507